Filing summary: Chavant Capital Acquisition Corp. (10-Q), quarter ended June 30, 2023
Entity clarification: The filing is by Chavant Capital Acquisition Corp., a shell company/SPAC proposing a combination with Mobix Labs, Inc.; it is not an operating-company 10-Q for Mobix Labs. The filing reports no Mobix Labs operating results.
Business context and reporting period
Chavant was formed to pursue a business combination and had not commenced operations or generated operating revenue through June 30, 2023. Its principal reported activity was pursuing the proposed Mobix Labs transaction. The interim financial statements are unaudited and cover the three and six months ended June 30, 2023, compared with the corresponding 2022 periods.
The proposed transaction contemplated Mobix Labs becoming a wholly owned subsidiary of a domesticated Delaware company expected to be named Mobix Labs, Inc. A related PIPE agreement provides for a proposed $30 million investment, subject to closing conditions.
Key financial metrics
| Metric | Q2 2023 / June 30, 2023 | Comparable / prior balance |
|---|---|---|
| Operating revenue | None | None |
| Net income (loss) | Q2: $(258,093); first half: $(570,153) | Q2 2022: $34,785; first half 2022: $639,144 |
| Operating expenses | Q2: $308,500; first half: $770,938 | Q2 2022: $426,465; first half 2022: $811,341 |
| Cash and trust investments | Cash outside trust: $39,880; trust: $9,312,428 | December 31, 2022: cash $175,788; trust $9,835,409 |
| Cash flow, six months | Operating: $(268,318); investing: $697,010; financing: $(564,600); net cash decrease: $(135,908) | 2022: operating $(259,138); financing $150,000; net cash decrease $(109,138) |
| Liabilities and liquidity | Total liabilities: $3,336,658; working capital deficiency: $1,872,219; sponsor loans drawn: $1,102,000 | December 31, 2022 total liabilities: $2,420,794; sponsor loans drawn: $662,000 |
No operating margins are meaningful because the company had no operating revenue. Net results included non-cash fair-value movements: the first-half 2023 warrant-liability change contributed $198,900 of income, while the PIPE derivative-liability change was a $222,921 loss. Trust interest income was $224,806 for the first half. The company reported no income tax expense.
Material changes versus prior comparable periods
- Chavant moved from net income in 2022 to a net loss in both the second quarter and first half of 2023. Results reflect expenses and changing fair values of warrant and PIPE derivative liabilities, as well as trust investment income.
- Trust assets decreased from $9.84 million at year-end to $9.31 million at June 30, partly following redemptions and trust withdrawals. Redeemable public shares declined from 953,033 to 856,042.
- Cash outside the trust fell from $175,788 to $39,880, while sponsor working-capital loans drawn increased from $662,000 to $1.102 million.
Outlook, risks, contingencies, and unusual items
- Going concern: Management says outside cash is insufficient to fund operations for the next 12 months absent a business combination. The filing identifies substantial doubt about the company’s ability to continue as a going concern; sponsor funding and completion of a business combination are not assured.
- Transaction and deadlines: The agreement’s outside date was extended to November 22, 2023. In a July 18, 2023 subsequent event, shareholders extended the SPAC’s business-combination deadline to January 22, 2024 and removed the $5 million net-tangible-asset redemption limitation. Transaction closing remained subject to conditions, including shareholder approval, regulatory conditions, and minimum net tangible assets after redemptions and the PIPE.
- Redemptions and trust: At the July 2023 extension meeting, holders redeemed 77,130 shares for $841,808. If no combination is completed by January 22, 2024, public shares are to be redeemed under the charter, while warrants may expire worthless.
- Nasdaq listing: Nasdaq notified the company that its listed-securities market value was below the $35 million continued-listing threshold. The stated compliance deadline was September 19, 2023; failure could lead to delisting. The filing notes that redemptions and removal of the redemption limitation may make compliance more difficult.
- Funding and obligations: A June 2023 sponsor note permits up to $500,000 of additional borrowing and bears 10% annual interest. As of June 30, none was drawn under that note. The filing reports $1.102 million of sponsor loans drawn at quarter-end; subsequent disclosures report additional draws. A $2.8 million business-combination marketing fee is contingent on closing.
- Controls: Management concluded disclosure controls were ineffective at June 30, 2023 because previously identified material weaknesses remained, including weaknesses related to accounting expertise, earnings per share, PIPE accounting, and review of third-party valuations.
- Other items: The PIPE includes a make-whole share feature tied to post-closing share-price performance; its derivative liability was $1.288 million at June 30 and is valued using significant unobservable inputs. The filing reports no legal proceedings.
The filing provides no operating-company guidance or revenue outlook; Chavant stated that it expects no operating revenue until after a business combination.
Most important facts for investors to verify
- Whether the Mobix Labs transaction closed, was amended, or was terminated, and whether all closing conditions and shareholder approvals were satisfied.
- Current trust balance, redemption levels, outside cash, sponsor-loan balances and terms, and the company’s ability to fund expenses through closing.
- Whether Nasdaq listing compliance was regained by the stated deadline and whether the securities remained listed.
- The status and potential dilution from the $30 million PIPE, including its make-whole feature and final fair value.
- Whether internal-control material weaknesses were remediated and whether subsequent filings disclose any accounting corrections or updated going-concern assessment.